Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,263.00+0.66%ETH$2,512.60+2.72%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
PA

NASDAQ · PAHC

Phibro Animal Health Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

$36.58

Down-$0.96 (-2.62%)

Updated Sep 12, 2026, 12:10 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.65B
P/E ratio
24.36
Dividend yield
1.31%
52-week range
$28.25 – $60.08
Volume
174.06K
Avg. volume
292.23K

Price performance

PAHC price history

1M range · 19 trading sessions · Daily adjusted prices

PAHC closed at $36.58 after 19 trading sessions, up 6.46% for the selected period.

Last close
$36.58
Period change
+6.46%
Period low
$34.36
Period high
$39.92
Daily close
View OHLC price history
PAHC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$36.80$36.96$36.295$36.58174.06K
Sep 9, 2026$37.11$37.4599$36.60$36.80176.89K
Sep 8, 2026$37.92$37.92$36.86$37.31182.19K
Sep 4, 2026$38.26$38.82$37.685$38.25176.42K
Sep 3, 2026$40.24$40.50$38.20$38.58174.64K
Sep 2, 2026$38.32$40.65$38.32$39.92324.24K
Sep 1, 2026$37.77$38.72$37.63$38.37370.17K
Aug 31, 2026$37.13$38.07$36.7239$37.74357.38K
Aug 28, 2026$36.36$38.65$36.36$37.67362.75K
Aug 27, 2026$39.39$39.39$35.01$36.35432.91K
Aug 26, 2026$36.48$36.79$35.735$36.09300.6K
Aug 25, 2026$35.71$36.105$35.30$35.93236.8K
Aug 24, 2026$36.32$36.735$35.105$35.31153.19K
Aug 21, 2026$35.41$36.44$35.29$36.32324.42K
Aug 20, 2026$35.26$35.89$34.63$35.18179.33K
Aug 19, 2026$35.00$36.12$35.00$35.44163.1K
Aug 18, 2026$34.92$35.09$34.20$34.6589.3K
Aug 17, 2026$34.03$34.85$33.7101$34.63152.63K
Aug 14, 2026$34.03$34.68$34.03$34.36110.78K

Latest PAHC news

The latest Smart Investors Daily articles mentioning PAHC.

Stock researchCompany · Overview

PAHC research

Overview

Company profile and research snapshot.

Company profile

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$34.00
Implied upside
—
Analysts
—
PAHC recent ratings
DateFirmRatingTarget
May 14, 2026CitigroupNeutral—
Apr 15, 2026CitigroupNeutral—
Nov 7, 2025JP MorganOverweight—
Aug 29, 2025B of A SecuritiesUnderperform—
Jul 7, 2025JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 5, 2026

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health earnings and guidance set the tone Phibro Animal Health (PAHC) drew investor attention after issuing earnings guidance for the fiscal year ending June 30, 2027, alongside reporting fourth quarter and full year 2026 results. The company now projects 2027 net sales of US$1.55b to US$1.60b and net income of US$122 million to US$132 million. Expected diluted EPS is US$2.98 to US$3.22. These figures follow 2026 sales of US$1,518.09 million and net income of US$99.72...

Yahoo · Sep 2, 2026

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Yahoo · Sep 1, 2026

Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year

Phibro Animal Health (NASDAQ:PAHC) closed out fiscal 2026 with numbers that speak for themselves. Full-year net sales topped $1.5 billion, adjusted EBITDA climbed 39% to $255 million, and adjusted diluted earnings per share jumped 48% to $3.22. The results, covering the quarter and year ended June 30, mark the first complete fiscal year since the […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By